WebFDA label information for this drug is available at DailyMed. Use in Cancer. Daratumumab is approved to be used alone or with other drugs to treat: Multiple myeloma. ... With pomalidomide and dexamethasone in patients who have received at least two therapies that included lenalidomide and a proteasome inhibitor.
Pomalyst (pomalidomide) - Medical News Today
Webinitiating POMALYST [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1, 8.3)]. 2.2 Recommended Dosage for Multiple Myeloma The recommended dosage of POMALYST is 4 mg once daily orally with or without food on Days 1 through 21 of each 28-day cycle until disease progression. Give POMALYST in combination with … WebPomalyst is taken in capsule form by mouth on days 1–21 of repeated 28-day cycles until disease progression. The dose is 4 mg per day orally (by mouth). Dosage is modified for certain patients with renal or hepatic impairment. Pomalyst should be taken at the same time of the day, with or without food. Swallow Pomalyst with water. culinary community
Pomalyst Information, Side Effects, Warnings and Recalls - Recall …
WebFeb 16, 2024 · Dosage for multiple myeloma. For multiple myeloma, the Pomalyst dosage is 4 mg taken once daily for the first 21 days of your 28-day treatment cycle. Then for the final 7 days of every treatment ... WebReferences. Dailymed."Pomalidomide: dailymed provides trustworthy information about marketed drugs in the united states. dailymed is the official provider of fda label information (package inserts).". WebPomalidomide is a yellow solid powder. It has limited to low solubility into organic solvents and it has low solubility in all pH solutions (about 0.01 mg/mL). Pomalidomide has a chiral carbon atom which exists as a racemic mixture of the R(+) and S(-) enantiomers. POMALYST is available in 1-mg, 2-mg, 3-mg, and 4-mg capsules for oral ... eastern zone trap shoot